Your Header

Gilead Charges $3,120 For Covid-19 Drug Developed With $70M In Taxpayer Money

Consumer advocates reacted with disgust Monday to an announcement by Gilead Sciences that it will charge U.S. hospitals around $3,120 per privately insured patient for a treatment course of remdesivir, a drug which has proven modestly effective at speeding Covid-19 recovery times.

Peter Maybarduk, director of Public Citizen’s Access to Medicines Program, called Gilead’s pricing—which works out to around $520 per dose for non-government buyers like hospitals—”an offensive display of hubris & disregard for a public” & slammed a Trump administration for failing to ensure that a price of a drug developed with substantial taxpayer support is affordable for all.

Maybarduk pointed to Institute for Clinical & Economic Review research showing Gilead could still make a profit by pricing remdesivir at $310 per course.

read more

Original post by Common Dreams and software by Elliott Back

Leave a Reply

XHTML: You can use these tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

eXTReMe Tracker